Chongqing Zhifei Biological Products (300122.SZ) has seven self-developed products on the market, one of which is conditionally listed, including vaccine products for preventing meningitis, pneumonia, and other infectious diseases.

Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform that the company has 7 proprietary products on the market and 1 proprietary product conditionally approved for listing, including vaccines for preventing infectious diseases such as meningitis and pneumonia, as well as drugs that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infections. The company has a total of 31 research projects, among which the quadrivalent flu vaccine is in the stage of applying for listing, and clinical trials of freeze-dried human rabies vaccine (MRC-5 cells) and influenza virus split vaccine have been completed. Five products including the 15-valent pneumococcal conjugate vaccine and fractional pertussis vaccine are in phase III clinical trials.

Gelonghui FinanceJul 5 05:20 ET

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Largest Shareholder, CEO Rensheng Jiang Sees Holdings Value Fall by 4.9% Following Recent Drop

Key Insights Significant insider control over Chongqing Zhifei Biological Products implies vested interests in company growth The top 2 shareholders own 54% of the company Institutional ownership

Simply Wall StJul 3 19:30 ET

Chongqing Zhifei Biological Products (300122.SZ): Respiratory syncytial virus (RSV) vaccine in the R&D pipeline is currently in the preclinical research stage.

On June 14, Gelonhui reported that an investor asked Chongqing Zhifei Biological Products (300122.SZ) on the investor interaction platform, "May I ask at what stage the company's RSV vaccine research and development is at?" The company replied that the respiratory syncytial virus (RSV) vaccine in its research and development pipeline is currently in the preclinical stage.

Gelonghui FinanceJun 14 04:40 ET

Chongqing Zhifei Biological Products is betting on a new vaccine, and wealthy investors in Chongqing have made new moves.

Planning to create a third listed company? Caixin Investor website reported that Zhifei Biological Products (stock code: 300122.SZ), a vaccine giant, has new actions from its actual controller. At the end of May this year, the company announced that the actual controller Jiang Rensheng pledged 6.895 million shares in the company for equity investments, who already has two listed companies before. This investment also makes the market curious about Jiang Rensheng's next capital layout. In the vaccine market, Zhifei Biological Products has gone from being on the brink of bankruptcy to having the highest market cap of over 300 billion yuan, reflecting not only the era but also personal business judgment. Jiang Rensheng himself has also crossed over from vaccines to innovative drugs and has successfully determined the capital investment each time.

China InvestorsJun 11 06:01 ET

Chongqing Zhifei Biological Products (SZSE:300122) Has A Pretty Healthy Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi

Simply Wall StJun 10 23:39 ET

It's worse than collecting! The HPV vaccine fell to the floor price, and the performance of leading companies was “in vain”

Future inclusion in immunization plans?

Gelonghui FinanceMay 21 23:52 ET